Empirical Finance’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15.4M | Buy |
61,181
+2,051
| +3% | +$441K | 0.64% | 26 |
|
|
2026
Q1 | $12.9M | Sell |
59,130
-99
| -0.2% | -$22K | 0.6% | 32 |
|
|
2025
Q4 | $13.5M | Sell |
59,229
-2,633
| -4% | -$600K | 0.65% | 21 |
|
|
2025
Q3 | $14.3M | Buy |
61,862
+596
| +1% | +$121K | 0.68% | 24 |
|
|
2025
Q2 | $11.4M | Buy |
61,266
+391
| +0.6% | +$72.7K | 0.6% | 27 |
|
|
2025
Q1 | $12.8M | Buy |
60,875
+727
| +1% | +$141K | 0.77% | 25 |
|
|
2024
Q4 | $10.7M | Sell |
60,148
-790
| -1% | -$145K | 0.62% | 28 |
|
|
2024
Q3 | $12M | Buy |
60,938
+1,303
| +2% | +$243K | 0.7% | 25 |
|
|
2024
Q2 | $10.2M | Sell |
59,635
-4,037
| -6% | -$669K | 0.64% | 26 |
|
|
2024
Q1 | $11.6M | Buy |
63,672
+2,138
| +3% | +$368K | 0.71% | 26 |
|
|
2023
Q4 | $9.54M | Buy |
61,534
+364
| +0.6% | +$53.1K | 0.67% | 27 |
|
|
2023
Q3 | $9.12M | Buy |
61,170
+5,936
| +11% | +$871K | 0.67% | 28 |
|
|
2023
Q2 | $7.44M | Buy |
55,234
+6,140
| +13% | +$900K | 0.58% | 31 |
|
|
2023
Q1 | $7.82M | Buy |
49,094
+2,917
| +6% | +$446K | 0.73% | 24 |
|
|
2022
Q4 | $7.46M | Buy |
46,177
+3,817
| +9% | +$585K | 0.77% | 26 |
|
|
2022
Q3 | $5.68M | Buy |
42,360
+6,838
| +19% | +$981K | 0.67% | 27 |
|
|
2022
Q2 | $5.44M | Buy |
35,522
+1,920
| +6% | +$293K | 0.69% | 27 |
|
|
2022
Q1 | $5.45M | Buy |
33,602
+3,714
| +12% | +$539K | 0.61% | 28 |
|
|
2021
Q4 | $4.05M | Buy |
29,888
+8,161
| +38% | +$964K | 0.48% | 37 |
|
|
2021
Q3 | $2.34M | Buy |
21,727
+1,286
| +6% | +$147K | 0.35% | 53 |
|
|
2021
Q2 | $2.3M | Buy |
20,441
+2,941
| +17% | +$331K | 0.38% | 50 |
|
|
2021
Q1 | $1.88M | Hold |
17,500
| – | – | 0.33% | 82 |
|
|
2020
Q4 | $1.88M | Buy |
17,500
+3,164
| +22% | +$304K | 0.33% | 82 |
|
|
2020
Q3 | $1.26M | Sell |
14,336
-12,171
| -46% | -$1.15M | 0.27% | 96 |
|
|
2020
Q2 | $2.6M | Buy |
26,507
+1,749
| +7% | +$154K | 0.67% | 24 |
|
|
2020
Q1 | $1.89M | Buy |
24,758
+3,088
| +14% | +$263K | 0.59% | 30 |
|
|
2019
Q4 | $1.92M | Sell |
21,670
-2,142
| -9% | -$178K | 0.47% | 29 |
|
|
2019
Q3 | $1.8M | Buy |
23,812
+20,250
| +569% | +$1.39M | 0.5% | 31 |
|
|
2019
Q2 | $259K | Sell |
3,562
-71
| -2% | -$5.58K | 0.07% | 141 |
|
|
2019
Q1 | $293K | Buy |
3,633
+831
| +30% | +$68K | 0.07% | 138 |
|
|
2018
Q4 | $258K | Sell |
2,802
-232
| -8% | -$20.4K | 0.08% | 130 |
|
|
2018
Q3 | $287K | Buy |
3,034
+329
| +12% | +$31.2K | 0.07% | 125 |
|
|
2018
Q2 | $251K | Sell |
2,705
-928
| -26% | -$90.6K | 0.06% | 121 |
|
|
2018
Q1 | $293K | Buy |
+3,633
| New | +$399K | 0.07% | 138 |
|
|
2017
Q4 | – | Sell |
-3,388
| Closed | -$302K | – | 97 |
|
|
2017
Q3 | $302K | Buy |
+3,388
| New | +$258K | 0.1% | 105 |
|
|
2017
Q1 | – | Sell |
-703
| Closed | -$45K | – | 89 |
|
|
2016
Q4 | $45K | Buy |
+703
| New | +$42.9K | 0.03% | 113 |
|
Other funds holding ABBV
Empirical Finance's ABBV Position: Q2 2026 in Review
Empirical Finance increased its AbbVie (ABBV) stake by 3.5% in Q2 2026, buying an estimated $441K and bringing the position to 61,181 shares worth $15.4M. The position accounts for 0.64% of the portfolio, ranked #26.
Empirical Finance first reported a position in ABBV in Q4 2016 and has held it in 36 quarters since. 4,192 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Empirical Finance held 61,181 shares of AbbVie worth $15.4M as of Q2 2026.
- Empirical Finance bought 2,051 AbbVie shares in Q2 2026, an estimated $441K.
- AbbVie made up 0.64% of Empirical Finance's portfolio in Q2 2026, its #26 holding.
- Empirical Finance first reported a position in AbbVie in Q4 2016 and has held it in 36 quarters since.
- 4,192 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Empirical Finance's 13F filing for Q2 2026, filed 14 Aug 2026.